Literature DB >> 12606024

Complement component anaphylatoxins upregulate chemokine expression by human astrocytes.

Anne-Christine Jauneau1, Alexander Ischenko, Philippe Chan, Marc Fontaine.   

Abstract

The complement (C) system, a major component of the innate immune system, has been described as a factor implicated in some brain disorders. C activation leads to the release of anaphylatoxins, two proinflammatory polypeptides acting through specific receptors that have been detected on brain cells. Here, we examined the effect of anaphylatoxins on chemokine expression by human astrocytes. We showed that anaphylatoxins significantly increase chemokine mRNA expression. However, anaphylatoxin-induced chemokine secretion (interleukin-8) was observed only in the presence of interleukin-1beta. Thus, anaphylatoxins could initiate a chemokine cascade and, at least in part, be involved in pathogenesis of the brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606024     DOI: 10.1016/s0014-5793(03)00060-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 2.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

3.  Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress.

Authors:  Noriko Shinjyo; Yolanda de Pablo; Milos Pekny; Marcela Pekna
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

4.  The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.

Authors:  Andrew Elvington; Carl Atkinson; Hong Zhu; Jin Yu; Kazue Takahashi; Gregory L Stahl; Mark S Kindy; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

Review 5.  Redox signaling and the innate immune system in alcoholic liver disease.

Authors:  Jessica I Cohen; Xiaocong Chen; Laura E Nagy
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

6.  CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model.

Authors:  Sarah A Ingersoll; Carol B Martin; Scott R Barnum; Brian K Martin
Journal:  Mol Immunol       Date:  2010-09-01       Impact factor: 4.407

7.  The complement system plays a critical role in the development of experimental autoimmune anterior uveitis.

Authors:  Purushottam Jha; Jeong-Hyeon Sohn; Qin Xu; Hiroki Nishihori; Yali Wang; Saori Nishihori; Balasubramanian Manickam; Henry J Kaplan; Puran S Bora; Nalini S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

8.  Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.

Authors:  Michele T Pritchard; Megan R McMullen; Feng Lin; M Edward Medof; Abram B Stavitsky; Jessica I Cohen; Laura E Nagy
Journal:  Gastroenterology       Date:  2007-02-01       Impact factor: 22.682

9.  An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice.

Authors:  Sanjoy Roychowdhury; Megan R McMullen; Michele T Pritchard; Amy G Hise; Nico van Rooijen; M Edward Medof; Abram B Stavitsky; Laura E Nagy
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 10.  Mutations of complement factor I and potential mechanisms of neuroinflammation in acute hemorrhagic leukoencephalitis.

Authors:  Lori Broderick; Chhavi Gandhi; James L Mueller; Christopher D Putnam; Katayoon Shayan; Patricia C Giclas; Karin S Peterson; Seema S Aceves; Robert M Sheets; Bradley M Peterson; Robert O Newbury; Hal M Hoffman; John F Bastian
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.